News
OCUL
4.090
+1.74%
0.070
Is Ocular Therapeutix (NASDAQ:OCUL) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Simply Wall St. · 06/13 17:23
BRIEF-Aurion Biotech Appoints Dr Michael Goldstein As President And Chief Medical Officer
reuters.com · 06/09 13:39
BRIEF-Ocular Therapeutix Announces Organizational Changes To Support Development For Retinal Diseases
reuters.com · 06/08 11:29
Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases
BEDFORD, Mass., June 08, 2022--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced senior leadership ch...
Business Wire · 06/08 11:00
Ocular Therapeutix's Return On Capital Employed Overview
Ocular Therapeutix (NASDAQ:OCUL) brought in sales totaling $13.19 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 225.77%, resulting in a loss of $12.54 million.
Benzinga · 06/06 15:04
Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference
BEDFORD, Mass., June 01, 2022--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will p...
Business Wire · 06/01 12:00
Piper Sandler Adjusts Price Target on Ocular Therapeutix to $10 From $16, Reiterates Overweight Rating
MT Newswires · 05/31 05:22
FANH, CARA and ACCD are among after hour and movers
Gainers: Fanhua (FANH) +7%. Ocular Therapeutix (OCUL) +5%. ThredUp  (TDUP) +5%. Cara Therapeutics (CARA) +3%. LegalZoom.com (LZ) +3%. Losers: Eton Pharmaceuticals (ETON) -21%. Allakos (ALLK) -7%. Accolade (ACCD) -5%. Sono Group  (SEV)
Seekingalpha · 05/27 21:49
Scholar Rock, Phathom top healthcare gainers; PolarityTE, Tonix lead losers' pack
Gainers: Scholar Rock (SRRK) +26%. Phathom Pharmaceuticals (PHAT) +12%. 4d Pharma  (LBPS) +10%. Ocular Therapeutix (OCUL) +9%. Magenta Therapeutics (MGTA) +8%. Losers: PolarityTE (PTE) -34%. Tonix Pharmaceuticals (TNXP) -22%. Albireo Pharma (ALBO) -18%. Ac...
Seekingalpha · 05/17 14:03
--Berenberg Bank Cuts Price Target on Ocular Therapeutix to $21 From $23, Maintains Buy Rating
MT Newswires · 05/11 07:50
Expert Ratings for Ocular Therapeutix
Over the past 3 months, 4 analysts have published their opinion on Ocular Therapeutix (NASDAQ:OCUL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade...
Benzinga · 05/10 17:03
--HC Wainwright Adjusts Price Target on Ocular Therapeutix to $10 From $14, Reiterates Buy Rating
MT Newswires · 05/10 09:26
Piper Sandler Adjusts Price Target on Ocular Therapeutix to $16 From $20, Reiterates Overweight Rating
MT Newswires · 05/10 07:23
Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 21:45
BRIEF-Ocular Posts Quarterly Net Loss Per Share, Diluted $0.22
reuters.com · 05/09 21:13
Ocular Therapeutix Q1 EPS $(0.22) Beats $(0.26) Estimate, Sales $13.19M Miss $14.20M Estimate
Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 8.33 percent increase over losses of $(0.24) per share from
Benzinga · 05/09 20:12
Ocular Therapeutix GAAP EPS of -$0.22 beats by $0.03, revenue of $13.19M misses by $0.77M
Ocular Therapeutix press release (NASDAQ:OCUL): Q1 GAAP EPS of -$0.22 beats by $0.03. Revenue of $13.19M (+79.7% Y/Y) misses by $0.77M. Guiding DEXTENZA Annual Net Product Revenue for 2022 between
Seekingalpha · 05/09 20:05
-- Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $13.2M, vs. Street Est of $13.96M
MT Newswires · 05/09 16:10
Earnings Scheduled For May 9, 2022
  Companies Reporting Before The Bell • Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
Benzinga · 05/09 08:52
Notable earnings after Monday's close
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT,
Seekingalpha · 05/08 21:35
More
Webull provides a variety of real-time OCUL stock news. You can receive the latest news about Ocular Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About OCUL
Ocular Therapeutix, Inc. is a biopharmaceutical company, which is focused on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its proprietary, bioresorbable hydrogel platform technology. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.